A school science project demonstrates that flipbooks can be a useful educational tool for patients and their families to learn about rheumatic conditions and their treatment.
Methotrexate Shows Promise for Hand Arthritis
Methotrexate—an affordable, established drug for rheumatoid arthritis—may also be helpful for patients suffering from osteoarthritis (OA) of the hand, a recent study reports.1 Treatment of hand OA and inflammation with 20 mg of methotrexate for six months had a moderate, but potentially clinically meaningful, effect on reducing pain and stiffness in patients with symptomatic hand…
Biosimilars to Denosumab Approved with an Interchangeable Designation
The FDA has approved the first interchangeable biosimilars for denosumab.
Research Review of Plant-Based Diet for Patients with Osteoarthritis or Rheumatoid Arthritis
About 30 years ago, early in his career as a rheumatologist, Dirkjan van Schaardenburg, PhD, says patients with osteoarthritis experienced terrible problems with inflammation. The landscape has improved to the point that “people can live with it now,” he says. But they still need help. For example, osteoarthritis affects 7% of the global population, according…
Can Repeat Injections Improve Knee OA Pain?
Promising Results from a Phase 3 Study SAN DIEGO—An investigational liposomal formulation of dexamethasone sodium phosphate (TLC599) for intra-articular injection is being studied to treat patients with knee osteoarthritis (OA). George Spencer-Green, MD, MS, chief medical officer of Taiwan Liposome Company (TLC), Cambridge, Mass., presented recent data on this agent in a late-breaking abstract session…
FDA Issues Boxed Warning for Denosumab & Approves a Generic NSAID
In January, the U.S. Food & Drug Administration approved indomethacin in an oral suspension, a generic version of Indocin Oral Suspension. The agency also issued a boxed warning and updated label for denosumab, warning of the risks of severe hypocalcemia in patients with chronic kidney disease.
To the Bone: Experts Discuss Developments in Osteoporosis Care
During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D.
Genetic Influence on OA
In 59,970 twins aged 35 years or older, Magnusson et al. compared how much genetics contributes to osteoarthritis (OA) with the genetic contribution to other rheumatic/musculoskeletal diseases (RMDs) in the same population, while exploring the role of shared genetics in OA and other RMDs. The researchers used data from the Swedish Twin Registry, in addition to the Swedish National Patient Register. They concluded that the heritability (i.e., the total genetic contribution to a trait) of OA is relatively large compared with other rheumatic musculoskeletal diseases.
No Pain, Much to Gain
SAN DIEGO—Pain is one of the most common symptoms of rheumatic disease, and this session at ACR Convergence 2023 was dedicated to understanding recent research concerning the relationship between pain and inflammation.
When Is Arthroplasty Recommended? New ACR/AAHKS Guideline Offers Considerations for Timing of Elective Hip or Knee Arthroplasty
The ACR released a new arthroplasty guideline in an effort to remedy significant & detrimental delays faced by osteoarthritis or osteonecrosis patients who require surgical intervention.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 46
- Next Page »